NeueHealth chief accounting officer sells $10,027 in inventory

MINNEAPOLIS—Jeffrey J. Scherman, Chief Accounting Officer of NeueHealth, Inc. (NASDAQ:NEUE), not too long ago offered a portion of his holdings within the firm. In response to a submitting with the Securities and Trade Fee, Scherman offered 1,368 shares of frequent inventory on January 6, 2025, at a weighted common worth of $7.33 per share. This transaction quantities to a complete worth of $10,027. The sale comes as NeueHealth shares present sturdy momentum, with a 44% achieve over the previous six months, in response to InvestingPro knowledge.

Following the sale, Scherman retains possession of 5,942 shares of NeueHealth. The sale was executed to cowl tax withholding obligations associated to the vesting of restricted inventory models, as famous within the submitting. The shares have been offered in a number of transactions, with costs starting from $7.18 to $7.50 per share. With a present market capitalization of $60.9 million and buying and selling effectively above its 52-week low of $3.79, InvestingPro evaluation suggests the inventory stays undervalued regardless of current positive factors. Subscribers can entry 12 extra InvestingPro Suggestions for deeper insights into NEUE’s monetary well being and market place.

In different current information, NeueHealth’s inventory goal has been decreased by RBC Capital from $8.00 to $7.00, sustaining a Sector Carry out ranking. The adjustment got here after the corporate’s third-quarter outcomes, which, regardless of exceeding expectations, revealed a 9.01% year-over-year decline in income. The corporate’s present ratio, a key liquidity indicator, additionally raised considerations at 0.68.

RBC Capital’s up to date outlook takes into consideration these outcomes whereas aligning the valuation with the upcoming fiscal interval. The unchanged steerage from NeueHealth’s administration group was one other issue thought-about on this revision.

The sustained Sector Carry out ranking implies that NeueHealth is anticipated to carry out in step with sector expectations, a impartial stance on the corporate’s anticipated efficiency in comparison with its trade friends. These current developments present traders with a revised benchmark for NeueHealth’s market valuation as per RBC Capital’s evaluation.

This text was generated with the help of AI and reviewed by an editor. For extra info see our T&C.